Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Nezu, Kunihisa; Okubo, Teppei; Shiraiwa, Manabu; Nozawa, Yoshihiro; Kyan, Atsushi

doi:10.1002/iju5.12210

IJU Case Reports

2020

DOI: 10.1002/iju5.12210

|View full text |Cite

Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Kunihisa Nezu¹,

Teppei Okubo²,

Manabu Shiraiwa³

et al.

Abstract: Abbreviations & Acronyms AE1/3 = cytokeratin AE1/AE3 CDX2 = caudal type homeobox 2 CEA = carcinoembryonic antigen CK = cytokeratin EGFR = epidermal growth factor receptor EMT = epithelialmesenchymal transition FOLFIRI = folinic acid, 5fluorouracil and irinotecan MRI = magnetic resonance imaging PSA = prostate-specific antigen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 10 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nezu et al . reported a case of coexisting mucinous urethral and prostate adenocarcinoma managed with systemic treatment 1 . They initially diagnosed a patient with prostate adenocarcinoma.…”

mentioning

confidence: 99%

Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Watari

Sadahira

2020

IJU Case Reports

View full text Add to dashboard Cite

mentioning

confidence: 99%

Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Watari

Sadahira

2020

IJU Case Reports

View full text Add to dashboard Cite

Secondary peripheral T-cell lymphoma and acute myeloid leukemia after Burkitt lymphoma treatment: A case report

Huang¹,

Meng²,

Liu³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Multiple primary cancer refers to more than one synchronous or sequential cancer in the same individual. Multiple primary cancer always presents as solid cancer or acute myeloid leukemia (AML) secondary to lymphoma. Here, we report a rare case of secondary peripheral T-cell lymphoma and AML after Burkitt lymphoma treatment. CASE SUMMARY A 54-year-old female patient was admitted to our hospital complaining of edema on her left lower limb. Physical examination revealed multiple superficial lymphadenectasis on her neck and pelvis. Color ultrasonography examination showed multiple uterine fibroids and a solid mass at the lower left side of the abdomen. Pathological biopsy revealed Burkitt lymphoma. After three hyper-CVAD (A + B) regimens, she achieved complete remission. Two years later, lymphadenectasis reoccurred. A relevant biopsy confirmed the diagnosis of peripheral T-cell lymphoma, which was accompanied by gastrointestinal invasion and hemocytopenia. Meanwhile, bone marrow examination revealed AML. On the second day of scheduled treatment, she developed gastrointestinal bleeding, peptic ulcers, and hemorrhagic shock and was critically ill. She was then discharged from the hospital due to financial concerns. CONCLUSION This is the first report of secondary peripheral T-cell lymphoma and AML after Burkitt lymphoma treatment with heterochronous and synchronal multiple primary cancers.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Cited by 2 publications

References 10 publications

Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

Secondary peripheral T-cell lymphoma and acute myeloid leukemia after Burkitt lymphoma treatment: A case report

Contact Info

Product

Resources

About